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Hepatocellular Carcinoma Cancer (HCC) is a highly aggressive cancer generally caused by 
chronic liver disease. A persistent, non-specific and ineffective activation of the immune 
system within the chronically infected liver has been proposed as the main cause of 
repeated cycles of tissue damage, repair and regeneration that eventually promote 
carcinogenesis. However, appropriate activation of the immune system can also prevent 
tumour progression. We hypothesized that the tumour immune microenvironment could 
affect the progression of established tumours and evaluated the potential immune 
mechanisms associated with clinical end point in HCC. 
Our results show that HCC patient survival is positively correlated with a proinflammatory 
innate immune gene signature within the tumours. This signature includes cytokines such 
as TNF/ IL-6 and LTA and two Toll-Like-Receptors(TLR): TLR3 and TLR4. Importantly, 
the expression of TLR3 is found to be positively associated with patient survival in two 
independent cohorts of patients. In addition, the survival-associated cytokines are mostly 
derived from tumour-infiltrating immune cells while TLR3 is expressed by both immune 
and tumour cells. We show that some HCC cell lines express TLR3 and stimulation of these 
cell lines with polyinosinic-polycytidilic acid (Poly I:C), a TLR3 ligand, results in an 
increase in TLR3 expression and subsequent tumour cell death by 24 hr. 
Proliferating immune cells, predominantly NK and T cells are also found in tumours of 
patients with longer survival. The density of these cells is correlated positively with cancer 
cell apoptosis and negatively with their proliferation. Our data identify TLR3-expressing 
leukocytes to be NK cells. NK cells express TLR3 and can upregulate TLR3 upon poly I:C 
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stimulation. Furthermore NK cells, even in the absence of antigen-presenting cells, 
upregulate IFN-γ secretion in response to poly I:C. Data from our lab showed that IFN-γ 
potentiates CXCL10 secretion by HCC cells and macrophages and that CXCL10 is 
attracting Th1 and NK cells. Therefore our finding suggest that poly I:C-induced 
expression of IFN-γ by NK cells can reinforce this paracrine loop, leading to increased 
activity towards tumours. NK cells isolated from PBMC of normal donors and treated with 
poly I:C showed increased expression of TLR3, granzyme B  and perforin. They also 
display an increased killing of HCC cells. 
Finally, TLR3 expression decreases with the advancement of the disease in HCC patients. 
Patients with lower grade and early stages of HCC have higher TLR3 expression than 
patients with higher grades and more advanced stages. This suggests that low expression of 
TLR3 by cancer cells confers a selective advantage for the tumour, since TLR3 can result 
in cell death of the tumour, either directly or through the action of immune cells such as 
NK cells. 
Therefore, an inflammatory environment within the HCC tumour could be an important 
means to control tumour progression via immune cells activation and proliferation. Such 
activation may be promoted by danger signals sensed by TLR such as TLR3 on both NK 
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1.  INTRODUCTION 
 
1.1  Hepatocellular Carcinoma: Incidence and Etiological factors 
 
Hepatocellular Carcinoma (HCC) is a primary malignancy of the liver epithelial cell 
and accounts for 90% of primary liver cancer. 5% of which are cholangiocarcinoma 
and the rest are of indeterminate origin. Angiosarcoma is extremely rare [1].  
HCC is the third leading cause of cancer-related death worldwide [2]. Due to its high 
mortality rate, the fatality ratio (overall ratio of mortality to incidence) of HCC is 
close to one, indicating that most patients who develop liver cancer will die. 
According to the recent statistics in 2008, there are 696 000 deaths per year from liver 
cancer worldwide [2,3].  
HCC has long been one of the most important cancers in the world, not only because of 
its high fatality ratio but also because it ranks highly in cancer frequency, being the fifth 
most common cancer in men and eighth in women. The incidence of HCC varies by 
geographical region. The incidence of HCC is higher in countries such as Africa, Asia, 
China and Africa compared to Europe, America and Australia/New Zealand. Global 
variations in incidence rates of HCC closely reflect the variation in risk factors for HCC. 
Therefore countries with a high occurrence of chronic hepatitis B virus (HBV) and /or 
hepatitis C virus have a higher incidence of HCC. This is consistent with the fact that 


















Table 1. Age standardized incidence rates for HCC 
All values expressed per 100 000 of the population in 2008 (data from globocan 2008 (adapted from[5]) 
 
HCC generally arises as a consequence of underlying liver disease. Viral causes such 
as HBV and HCV  as well as non-viral causes such as chronic alcoholism, tobacco 
use or family history such as diabetes, obesity, non-alcoholic steatohepatitis can 
promote an inflammatory condition which when it becomes a chronic condition can 
lead to cirrhosis. Figure 1 shows the different etiological agents for the development 
of HCC in the Asia Pacific region [3,6]. Cirrhosis is the condition in which scar tissue 
replaces healthy liver tissues, impairing the function of the liver. In this chronic 
inflammatory condition, and together with accumulated mutations, patients with 
cirrhosis may develop HCC.  
Other causes such as water contamination with Aflatoxin B that can cause DNA 
mutations, which can result in oncogene activation or loss of tumour suppressor genes. 
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Aflatoxin contamination can also act synergistically with HBV in the pathogenesis of 
HCC [7]. The integration of  HBV genome after infection, and viral genes such as 
HBx, which can activate a variety of cellular promoters such as NK-κB and interfere 
with signal transduction pathways such as JaK1 and MAP kinases, may also account 
for the small percentage of cases which are associated with the development of HCC 
in the absence of cirrhosis [8]. 
The incidence of HCC is higher in males than in females. This striking gender 
disparity in the incidence of HCC suggests an important role of sex hormones in HCC 
pathogenesis. In a study by Naugler et al, the authors showed that estrogen could 
inhibit the secretion of IL-6 from Kuppfer cells and lead to a reduced chronic 
hepatitis [9]. Other effects such as the tumorigenic effect of androgens could also play 
a role in HCC. Inhibition of androgen in male mice leads to cell cycle arrest and 
induction of apoptosis due to increased synthesis of transforming growth factor-β 
1(TGF-1)[10]. The expresson of VEGF, a target gene for androgen receptor in liver, 
have also reported to be enhance by androgen receptor and HCV infection [11]. 
Despite the associations of estrogen and androgen in HCC, hormonal treatments with 






Figure 1. Odd ratios for the different etiological agents for the development of HCC. 





1.2  Current management strategies for HCC 
 
The development of HCC in patients with cirrhosis is a stepwise process that starts 
with the development of nodules. As the disease progress, small vascular invasion 
leads to intrahepatic invasion and systemic dissemination. With further progression, 
the tumours can extend into larger hepatic vessels. Once this occurs, curative 
treatment is rarely possible. HCC has therefore been a difficult target for systemic 
therapies. Most of the available treatments are physical, which usually directly attack 
the tumour or its blood supply. The fact that most cases of HCC develop in the 
presence of cirrhosis with impaired liver function poses an additional challenge to 
HCC treatment.  
For the few patients with no cirrhosis, or for those with preserved liver functions and 
who develops HCC in one region of the liver, resection is the preferred option. 
However, only 20-30% of patients are eligible for such treatment because of 
advanced or multifocal disease. Liver transplantation is another preferred treatment 
options for HCC because it can firstly remove the tumour with any intrahepatic 
metastasis and secondly, cures the underlying cirrhosis. However, the lack of 
available organs have resulted in strict selection criteria so that only those patients 
with early HCC and the highest likelihood of survival after transplantation are chosen 
to undergo this procedure. Other non-surgical treatment for HCC includes 
percutaneous ablation (PEI) which works by directly injecting alcohol into the 
tumours and radiofrequency ablation, which involves inserting an electrode into the 
tumour and applying radiofrequency energy to destroy the tumours. Both methods are 
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effective in destroying small tumours. However in all of the above treatments, 70% of 
the patients usually relapse within the first 5 years. In addition, the major drawback of 
these techniques is that they do not work for larger tumours. For bigger tumours, 
TACE (transarterial chemoembolization ), a method where an angiogenic catherer is 
inserted into the branches of the hepatic artery and a chemotherapeutic agent such as 
deoxyrubin is injected, combined with a occluding reagent such as polyvinyl beads 
where they lodge the vessels, can cause tumour necrosis.  For more advanced stage 
patients, Sorafenib, a tyrosine kinase inhibitor, has led to some positive results but the 
benefit of these treatments is only an additional 3 months disease-free survival after 
which the patients relapse again. Commonly administered chemotherapies, such as 
Tamoxifen, Octreotide and interferons showed no impact on patient survival [14].  
In conclusion, while resection and transplantation remains the most successful 
treatments for HCC, there is no first line systemic therapy that has emerged for 
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Figure 2. Diagram illustrating staging classification and treatments available for HCC.  







1.3 Activation of the immune system has been associated with liver cirrhosis 
 
The majority of HCC patients are usually chronically infected with HBV or HCV. 
The virus usually replicates non-cytopathically within the primary hepatocyte, and in 
the early phases of infection, there is no evidence of hepatocyte damage. Therefore 
persistent, non-specific activation of the immune system within the chronically 
inflamed liver had been proposed as the main cause of repeated cycles of tissue 
damage, repair and regeneration that eventually promote carcinogenesis [16,17].  
The first step in the disease progression is usually the activation of virus-specific 
cytotoxic T lymphocytes (CTL) after antigen recognition. These CTL then kill a 
small number of hepatocytes via the Fas- and perforin-mediated pathway and produce 
anti-viral cytokines (such as IFN-γ) that inhibit HBV replication non-cytopathically in 
a greater number of cells. The same cytokines can activate the liver cells to produce 
chemokines (such as CXCL5, CXCL9 and CXCL10) that recruit non-antigen-specific 
cells for example neutrophils into the organs. Production of matrix metalloproteinase 
(MMP) by these neutrophils in addition to chemokine induction may contribute to the 
migration of non-antigen specific lymphocytes for example, Natural Killer cells (NK), 
T cells and macrophages into the liver and lead to amplification of liver disease, 
initiated by cytotoxic T lymphocytes (Figure 3) [18].  
Liver repair in response to immune-mediated injury involves inflammatory and 
fibrogenic processes that resemble wound healing. Various cell types participate in 
this reparative mechanism such as hepatic stellate cells, myofibroblasts and Kupffer 
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cells. These cells resides in the liver while other cells such as monocytes, NK cells 
and T cells (for removal of debris and antigens) reach the liver from the circulation. 
Initially beneficial reparative response can become deleterious, leading to excessive 
extracellular matrix deposition within the liver. Therefore, persistent viral and 
recurrent immune-mediated liver damage can drive the pathogenesis of fibrosis and 
cirrhosis [18,19]. In the absence of viral infection, iron, copper or ethanol 
accumulation or biliary tract disorders can result in chronic inflammation, which 




Figure 3. Mechanism of Cytotoxic T- lymphocyte (CTL)-induced liver disease and viral clearance.  
(1) Antigen recognition by virus specific CTL leads to hepatocyte killing via the Fas L- and perforin –mediated 
pathways. (2)  CTL produces anti-viral cytokines that can inhibit HBV replication. (3) These cytokines can 
activate hepatocytes to produce chemokines (CXCL10) to recruit non-specific polymorphnuclear cells. (4) 
Production of MMP in addition to (5) chemokines induction can lead to migration of antigen–nonspecific 
lymphomononuclear cells. These cells can then (6) lead to amplification of the disease initiated by CTL. (Guidotti, 




1.4  Appropriate activation of the immune system can control tumour 
progression 
 
The paradoxical role of the immune system as crucial regulators of cancer 
development has been much debated. Association of the inflammation with cancer 
has been known for over a century [21]. Leukocytic infiltrates in and around 
neoplasmas, represent an attempt by the host to eradicate tumour cells. Indeed, 
extensive infiltration of NK cells in human gastric or colorectal carcinoma is 
associated with a better prognosis [22,23]. On the other hand, tumours that contain 
immune cell type infiltrates such as macrophages in human breast cancermast cells in 
lung cancertend to be associated with an unfavorable prognosis [24-26]. 
Under certain conditions, inflammation seems to promote carcinogenesis and in other 
situations, to have an anti-tumour effect. In most cases, inflammation associated with 
cancer is similar to that seen in chronic inflammation, where growth factors, MMPs, 
chemokines and angiogenic factors stimulate tissue repair and promote cancer cell 
survival, implantation and growth [27,28]. Occasionally however, and for unclear 
reasons, this reaction shifts towards an inflammatory process, similar to acute 
inflammation, and can lead to spontaneous or treatment induced cancer regression 
[29]. Tumour disruptive inflammatory responses include cells such as M1 
macrophages, DC, T cells, B cells and NK cells [30]. Although tumour-specific 
lymphocytes are supposed to control and eradicate tumours, results from others have 
shown impairments in the functional status of these cells. Tumour-specific infiltrating 
lymphocytes express low levels of granzyme, perforin and fail to produce interferon-γ 
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in response to stimulation, although they could still produce interferon-γ if TCR 
signaling is bypassed. Thus these antigen-specific anti-tumour lymphocytes are 
rendered functionally tolerant by tumour microenvironment [31,32]. What is then the 
triggering event/s that can turn a quiescent immune response into a potent 
inflammatory response? 
In the proposed danger model of immunity, danger signals trigger innate immune 
response leading to recruitment, activation and survival of immune cells in the 
affected region [33]. Tumour environment usually does not have the requisite danger 
signals. Thus vaccines specific to tumour antigen have been very effective in the 
induction of T cells but tumour exposure is not sufficient in itself to activate cytotoxic 
T lymphocytes in the target organ and secondary stimulations are needed to activate 
their effector functions. Because cancer do not provide this co-stimulation, T cells 
remain non-functional on their encounter with tumour cells [33,34]. The challenge is 
then to deliver these danger signals necessary for lymphocyte activation to the tumour 
site. Clinicians have used Toll Like Receptor 7 (TLR7) agonists to treat skin 
melanoma, for example, Imiquimod which destroys cancer cells selectively though an 
immune mediated mechanism [35,36]. TLR agonist mimicking single-stranded RNA, 
activate plasmacytoid dendritic cells to secrete type I interferons and induce T and 
NK cell activation, which in turn can secrete interferon-y. The activated lymphocytes 
can then induce destruction of target cells, feeding tumour antigens to antigen 
presenting cells and lead to the recruitment of more lymphocytes (Figure 4) [37,38]. 
Acute inflammatory responses induced by TLR agonists are able to overcome anti-
inflammatory mechanisms and provide co-stimulation not found in chronic 
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inflammation. Therefore, by appropriately activating an immune response, tumour 
progression can be controlled. 
 
Figure 4. Postulated mechanism of immune mediated cancer rejection.  
The dotted line represents the separation between the local tumour microenvironement and the systemic immune 
system. (Mantovani et al, [38]) 
 
Although the importance of inflammation in liver carcinogenesis had been studied in 
detail, less is known about its impact on cancer progression. The tumour 
microenvironment consists of fibroblasts, endothelial and immune cells. These cells 
play a crucial role in tumour development, control and response to treatment [21,39]. 
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In breast, colorectal and lung cancer, the status of the stromal and local adaptive 
environment are superior prognostic factors compared to the tumour phenotype and 
clinical staging [39-41]. In HCC, infiltration of regulatory T cells is associated with a 
poor prognosis [42], while a significantly lower recurrence rate and improved 
survival were reported in HCC patients with marked lymphocyte infiltrate such as 
CD8+ T lymphocytes and B cells in the tumour [43]. More recently, work by Budhu 
et al have shown a predominantly Th1 signature in the liver tissue of HCC patients 
that were less likely to develop metastasis [44]. Additional gene signatures predictive 
of HCC patients survival have been previously identified in HCC [45]. However, 
little focus was given to immune-specific genes.  
Based on the hypothesis that immune phenotype of HCC tumours may be related to 
patient survival, we studied the type of tumour infiltrating immune cells and their 
functional polarization in resected HCC patients’ samples. Our results indicate that 
the immune microenvironment is more inert compared to adjacent non tumour tissues, 
with neutrophils and CD8+ T cell densities 2-60-times higher in the non-tumours 
compared to the tumour areas. This shows that the tumour area have a lower number 
and a weaker activation status of the infiltrating immune cells. We found that HCC 
patient survival is positively associated with higher expression of a group of 
inflammatory and innate immune genes within the tumour. High expression of 
inflammatory genes such as TNF and IL6 as well as innate immune genes such as 
TLR3 and TLR4 are associated with longer patient survival (Figure 5A). In addition, 
our results show that most of these survival associated molecules are derived from the 
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tumour infiltrating immune cells, except for TLR3 which is expressed by both the 










Figure 5. High levels of innate immune genes in HCC core tumours are associated with prolonged patient 
survival.  
Kaplan Meier survival probability graphs of patients with high (full line) and low (dotted line) expression of 11 
genes associated with longer patient survival. (B) TLR3 expression (by immunohistochemistry) by both the 




1.5 Toll-Like Receptors  
 
Toll-like receptors are pattern recognition receptors that recognize pathogen 
associated molecular patterns (PAMPs). They activate transcription factors 
facilitating the initiation of innate immunity response. In this way, the host system is 
able to promptly defend against any invading microorganisms. A total of 13 
mammalian TLR have been identified. TLR1, 2, 4, 5 and 6 are expressed on the cell 
surface and TLR3, 7, 8 and 9 are expressed on the endosome-lysosome membrane. 
Figure 6 shows the respective ligands for TLR. TLR 1, 2 and 6 recognise bacterial 
lipopeptides, TLR4 and 5 are the receptors for gram negative bacterial cell wall 
components, lipopolysaccharides (LPS), and flagellin respectively. Intracellular 
TLR3, 7/8, and TLR9 detect viral derived and synthetic double-stranded RNA, viral 
related single-stranded RNA and bacterial unmethylated CpG-DNA, respectively. 
The ligands for TLR 10, 12 and 13 remain unidentified [47]. 
In addition to recognizing PAMPs derived from microbes, these TLR also sense 
endogenous components derived from dying host cells, termed damage-associated 
molecular patterns (DAMPs). TLR4 detects endogenous ligands, such as high 
mobility group box 1, (HMGB1) [48], hyaluronan, heat shock protein 60 and free 
fatty acids. Reports have also demonstrated that necrotic cells can stimulate TLR2 
and 4 [49].  
DAMPs such as RNA from damaged tissues can serve as ligand for TLR3[50,51]. In 
an inflammatory situation, release of such endogenous ligands, from dead or dying 
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cells, are not uncommon. TLR3 is shown to be an endogenous sensor of tissue 





Figure 6.  Schematic overview of TLR signaling pathways. 
TLR 1, 2, 4, 5 and 6 are located on the cell surface while TLR 3, 7, 8 and 9 are expressed on the endosome 
membrane. All TLR, except for TLR3, signal through MyD88 while TLR3 and 4 uses TRAF for downstream 




All TLR, except for TLR3, associate with the common adaptor molecule MyD88 
through their intracellular TIR domain to trigger inflammatory responses. MyD88 
signals through TIRAP, TRIF and TRAM to induce NK-kB, activator protein 1 and 
interferon regulatory factors (IRF). TLR3 and 4 uses another adaptor molecule, TRIF, 
to induce type I IFNs. TRIF associates with TRAF and TBK1, leading to type 1 
interferon transcription. TRIF also associates with RIP1 to activate NK-κB for the 
synthesis of proinflammatory cytokines and recruit Fas-associated death domain 
(FADD) resulting in apoptosis through activation of caspase 8 [53].  
 
1.5.1 Role of TLR3 in anti-viral detection 
 
TLR3 recognizes dsRNA, either from virus replicating within cells, lysed virus- 
infected cells or synthetic dsRNA such as polyriboinosinic;polyribocytidylic acid 
(poly I:C). Because of its ligand, TLR3 has often been implicated in anti-viral 
immunity. Data from others have shown that cytokines are induced in a TLR3-
dependent manner in bronchial epithelial cell lines upon infection with ssRNA virus 
such as influenza. Virus-induced CXCL10 and CCL5 are impaired in the absence of 
TLR3 [54].  
DsRNA can also be recognized by other intracellular recognition receptors such as 
the RNA helicase RIG1 and the melanoma differentiation associated gene (MDA5). 
RIG-1 recognises cytosolic uncapped single stranded RNA generated by viral 
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polymerases. MDA5 senses synthetic poly I:C [55]. Upon binding of ligand, RIG1 
and MDA5 bind through caspase recruitment domain to mitochondria IPS-1, 
initiating signal cascades that lead to the activation of IRF3/7, NF-κB and AP1, 
followed by type I interferons induction [56]. 
It is probable that during the course of a viral infection, dsRNA comes into contact 
with both the cytoplasmic receptors RIG1 and MDA5 or TLR3. So why does a cell 
need different mechanisms to recognise dsRNA? This question is especially puzzling 
because the signaling pathways for TLR3 and RIG1/MDA5 seem to overlap 
significantly, in that all 3 would activate NK-κB and activate IRF3/7. Furthermore 
apoptosis is induced not only by TLR3 but also RIG1 [57]. 
 
1.5.2 Localization holds the key to TLR3 activity 
 
The answer to this question might lie in the intracellular localization and cellular 
expression pattern of TLR3 as compared with that of RIG1. TLR3 localises to an 
intracellular compartment in dendritic cells and cannot be detected on the cell surface 
[58]. This compartment has been reported to be endosomal because inhibition of 
endosomal acidification removed poly I:C signaling. Therefore, TLR3 has to 
encounter dsRNA in these vesicles, which is probably achieved through phagocytosis 
of dsRNA released into the extracellular spaces by necrotic or virally lysed cells. 
Virus can also gain entry into the cell through receptor mediated endocytosis. In 
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contrast to TLR3, RIG1 and MDA5 are cytoplasmic receptors and are therefore more 
suited for the direct recognition of dsRNA produced during viral replication.  
The cytoplasmic linker of TLR3 contains a sequence motif that is important for 
intracellular targeting of TLR3, since deleting this linker region interferes with 
normal intracellular targeting and causes cell surface expression of TLR3. This 
intracellular targeting of TLR3 leads the receptor to the same cytoplasmic membranes 
where TLR7 is localized and adjacent to phagosomes containing apoptotic cell 
particles. The fusion of such phagosomes to TLR3-containing endosomes might 
enhance the access of TLR3 to dsRNA that is derived from apoptotic vesicles [59].  
 
1.5.3 Roles of TLR3 in antiviral and crosspriming responses. 
 
TLR3 displays a distinct intracellular localization compared to RIG1 and MDA5 and 
has therefore been reported mainly in immune cells which have the ability to 
phagocytose or endocytose dsRNA. While TLR7, 8 and 9 are endosomal, they are not 
found in the same cell types as TLR3. TLR7 and 9 are found in plasmacytoid DC 
while TLR3 are found in myeloid DC, specifically in human monocyte-derived DC 
and CD11b+ DC as well as in murine CD8α DC [60]. TLR3 is reported to have a role 
in cross-priming. Poly I:C-treated tissue cells stimulated the upregulation of co-
stimulatory molecules on DC more efficiently then free poly I:C [61]. In addition, 
dsRNA on myeloid DC can also result in anti-tumour NK activation [62].  TLR3 is 
also reported to be expressed on macrophages, mast cell and NK cells.  NK cells are 
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major players in anti-viral immunity. As NK cells express TLR3, they can also be 





1.6 TLR3 expression on tumour cells 
 
In addition to mediating an antiviral host immune response, TLR3 has been 
implicated as a crucial danger signaling receptor that, through its presence on both 
immune and non-immune cells, is involve in the balance between tolerance, 
inflammation and disease [66].  Reports have shown that TLR3 triggering on mDC 
and macrophages leads to the production of IFN-α and TNF-α, which induces the 
secretion of CXCL9 by hepatocytes; CXCL9 then serves as an effective 
chemoattractant for CD8+ T cells which are suggested to cause liver damage [67,68].  
The role of TLR3 in cancer has been well studied through the adjuvant role of dsRNA 
in tumour vaccination. Most notably,  it promotes antigen cross-presentation by 
dendritic cells and the induction of enhanced primary and memory CD8+ T cell 
responses [61,69]. However, TLR3 have also been found to be expressed on non-
immune cells, such as keratinocytes or endothelial cells [70]. More importantly, 
reports of TLR3 on tumour cells have increased in recent years. TLR3 expression is 
found in human melanoma cancer cells and the triggering of this receptor can result in 
an upregulation of TLR3 mRNA. Treatment of these melanoma cells can induce 
inflammatory factors and upregulate cytokines such as CCL2 and CXCL10 [71].  
Data from Salaun group have also shown TLR3 expression in breast cancer cells and 
the treatment of these cells with poly I:C can result in massive apoptosis and 
inhibition of proliferation [72]. Interestingly, this in vitro data correlates with the 
results of a retrospective study on breast cancer treated with poly A:U (a synthetic 
TLR3 agonist) and results show that only patients with TLR3-positive tumours 
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benefited from the treatment and showed increased overall survival [73]. Similarly 
TLR3 was found to be over-expressed in 70% of primary and metastatic clear cell 
renal cell carcinoma (CCRCC) patients and a growth inhibitory effect is seen when 





1.7 The relevance of TLR3 in HCC tumours cells  
 
Recent studies have shown that TLR3 plays an important role in the pathophysiology 
of a variety of liver diseases [20,47,75] . This may be attributed to the wide 
expression of TLR3 on all types of liver cells, including hepatocytes [76,77], stellate 
cells [78], sinusoids endothelial cells [79], kupffer cells, billary epithelial cells [80], 
as well as immune cells such as NK cell, NKT cells [81] and liver lymphocytes [79] . 
Data from HCC mouse models have mostly shown the relevance of TLR3 in immune 
cells in promoting liver inflammation [63,82]. However, data on the role of TLR3 in 
non-haematopoetic cells are few. Nevertheless, observing the effects of TLR3 on 
these mouse models in liver inflammation, fibrosis and regeneration can shed some 
light on the effect of TLR3 in tumour cells. By using TLR3-chimeric mice in a Con A 
induced mouse model of acute hepatitis, Xiao et al showed increased expression of 
TLR3 on liver lymphocytes as well as sinusoidal endothelial cells. Disruption of 
TLR3 gene abolished Con A liver injury. More importantly, the group demonstrated 
that TLR3 signaling in both hematopoietic and non- hematopoietic cells play a critical 
role in Con A induced liver inflammation [79]. 
In the context of liver regeneration, Khavelsky and others have demonstrated the 
important role of TLR3 in regulating hepatocyte proliferation. Using TLR3 deficient 
mice, the group was able to show earlier hepatocyte proliferation and an increase in 
liver regeneration following partial hepatectomy (PHx). In the absence of TLR3, 
hepatocyte proliferation was accelerated. Using wild-type mice, the group showed 
that TLR3 signaling was being induced at the early time points of PHx, increasing the 
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levels of Rip3 and activation of caspase 8. These results suggest that TLR3 signaling 
plays an important role in inhibiting liver regeneration [83].  
Liver fibrosis, the condition which favours HCC development, is characterized by 
hepatic stellate cells (HSC) activation and accumulation of extracellular matrix 
proteins. Gao et al, have shown that treatment of mice with poly I:C markedly inhibits 
liver fibrosis. There are several mechanism to explain the poly I:C-mediated 
inhibition of liver fibrosis. Firstly, poly I:C induces NK cell activation and activated 
NK cells then kill early activated or senescence activated HSC that have increased 
expression of NK cell activating ligands [84,85]. Second, poly I:C induces NK cells 
to produce IFN-y and subsequently induces HSC apoptosis and cell cycle arrest [86]. 
Recent data have also shown that poly I:C treatement on HSC can lead the cells to 
produce type I interferons that may inhibit their proliferation [78,87], thereby 
contributing to suppression of liver fibrosis.  
Recent reports in humans demonstrate the expression of TLR3 in HCC tumours. 
Using human HCC cell lines, Khavelsky et al shows that transfection of poly I:C into 
the cells can trigger TLR3 downstream signaling molecules and lead to apoptosis of 
the tumour cells [76]. In addition, the group by Yoneda has also found expression of 
TLR3 in HCC patients samples and again after transfecting poly I:C into HCC cell 
lines they observed upregulation of TLR3 downstream signaling molecules such as 




1.8 The Role of TLR3 in Hepatic Cell Death. 
 
The liver is especially susceptible to injury and cell death due to its central role in 
metabolism including drugs, alcohol, lipid and fatty acid metabolism, enterohepatic 
circulation of bile acids and prevalence of hepatotropic viruses. Apoptosis and 
necrosis are the most widely recognized forms of hepatocyte cell death. Apoptosis is 
defined as a morphological aspect of cell death characterized by membrane blebbing, 
shrinkage of the cell, chromatin condensation and nuclear fragmentation. These 
apoptotic bodies are then phagocytosed by hepatic stellate cells and Kupffer cells 
which are the resident macrophage of the liver. Although apoptosis is usually a 
quiescent event, enhance hepatocyte apoptosis can lead to fibrosis and inflammation. 
In these conditions, following the engulfment of apoptotic bodies, Kupffer cells can 
upregulate death receptor ligands, capable of inducing death receptor-mediated 
apoptosis in hepatocytes, which may further aggravate liver inflammation [89]. 
Unlike apoptosis, which is mediated by well- defined pathways, necrosis is thought to 
represent accidental form of cell death. It results in the formation of plasma 
membrane blebs, which in contrast to apoptosis are devoid of organelles. Thus 
necrosis is accompanied by complete release of cellular constituents into the 
extracellular environment, a pathological phenomenon that can elicit a significant 
inflammatory response. A cellular feature of necrosis is the rupture of the plasma 
membrane which occurs during a “metastable state” resulting in bleb rupture [90]. 
Other forms of cell death in the liver which are less well understood, includes 
necroptosis and autophagy. 
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Pathogen-triggered apoptosis is a conserved innate immune defense mechanism. 
While recognising pathogen associated molecular patterns can trigger innate 
immunity, host cells also rely on apoptosis of infected cells as a way to prevent 
microbe spreading throughout the host cells. Hence the activation of TLR usually 
triggers 2 cellular programs: cell survival with the production of protective cytokines 
[91] and apoptosis to eliminate infected cells [92]. 
Data mentioned above have shown that TLR3 engagement can result in the induction 
of apoptosis. Apoptosis is a form of programmed cell death that results from 
sequential activation, through proteolytic cleavage, of a family of cysteine proteases, 
the caspases. Two major apoptotic pathways have been described: the “extrinsic 
pathway”, typically engaged after death receptor ligation and mediated by the initiator 
caspase 8, and the “intrinsic pathway”, typically triggered by DNA damage-inducing 
agents that bring about mitochondria membrane depolarisation, cytochrome c release 
in the cytoplasm and activation of the initiator caspase 9 [93].  
TLR3 signaling initiates the TRIF dependent signaling pathway the type I IFN 
pathway, both of which can lead to apoptosis. The TRIF dependent pathway is 
initiated primarily by caspase 8 and executed by caspase 3 [94]. The production of 
IFN-I antagonizes the CDK/cyclin/AKT mediated phosphorylation which leads to the 
stabilization of p27, preventing cell cycle entry and finally inducing apoptosis of the 






1.9 Natural Killer cells and their relevance to HCC 
 
As blood circulating to the liver is rich in bacterial products and toxins, the liver relies 
on its immune system to quickly defend against against these potentially harmful 
pathogens without launching a harmful immune response. Eighty percent of the liver 
volume is composed of hepatocytes while the remaining cells are endothelial cells, 
stellate cells, Kupffer cells and lymphocytes. The immune cell comprises mainly 
phagocytic cells such as neutrophils and macrophages, lymphocytic cells such as NK 
cells, NKT cells and T cells. The role of immune cells such as dendritic cells, CD4 
and CD8 T cells, as well as T regulatory cells has been described in liver cancer. In 
HCC, infiltration of regulatory T cells and CD8 T cell impairment is associated with 
poor prognosis. Higher number of DC is also found to be associated with longer 
tumour-free survival in HCC patients [42,95-97].   
Mouse liver consists of about 10% NK cells while rat and humans liver contain about 
30-50% NK cells among the total lymphocytes. In humans, the proportion of NKT is 
<1 [98]. This is supported by evidence in mice showing that depletion of NK/NKT 
cells markedly enhances tumour metastases in the liver, and the augmentation of NK 
cells attenuates it [99-101]. In addition, NK cells can also secrete cytokines after 
activation, which makes them able to respond quickly to any invading microbes/cells.  
Many studies in human have reported that NK cell function is impaired in patients 
with liver cirrhosis, a major risk factor for HCC [102,103]. The frequency and 
function of liver and peripheral NK cells have also been reported to be decreased in 
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HCC patients [104-106]. Since the anti-tumour effect of NK in several tumour 
models including metastatic tumour has been well documented [107,108], it is 
generally believed that reduction of NK cells number and activity in HCC or cirrhotic 
liver is associated with progression of HCC. 
Although NK cells have been suggested to limit the growth of tumours in HCC, 
mechanistic explanation for how NK are recruited or activated in the liver remains to 
be elucidated.  Interestingly, it has been noticed that for many years that the injection 
of mice with poly I:C can lead to NK cell accumulation and activation in liver 
[100,109]. The effect of poly I:C stimulation on TLR3 in myeloid DC or monocytes 
leading to anti-viral or anti-tumour NK activity have been well documented 
[61,62,68,69,82] . However recent evidence has show that NK cells can be activated 
directly by poly I:C, with increased cytokine production and increased cytotoxicity 
against NK-sensitive cell lines and other tumour cell lines such as melanoma 
[63,64,110,111]. However the role of TLR3 in human NK cells in the context of HCC 
remains to be explored and activation of NK cells could be a novel therapeutic target 




1.10 Clinical use of TLR agonists 
 
Microbial components have been used to enhance anti-cancer immune response for 
many years. The anti-cancer effects of these microbial components are mediated 
through TLR signaling [112,113]. For example, the use of BCG as the Freund 
adjuvant, enhances the cytotoxicity of T cells and macrophages against cancer cells 
and induces in vivo anti-tumour cancer effect via-TLR2 and 4 [114]. TLR provides 
the means of recognition of PAMPs and most notably DAMPs by cells of the innate 
immune system [115]. Engagement of TLRs on DC promotes cross talk between the 
innate and adaptive immune system, maturation and migration of DC into lymph 
nodes leads to activation, proliferation and survival of tumour-specific naïve CD4+ 
and CD8 T cells. Tumour cells themselves do not express molecules which would 
induce DC maturation hence the use of TLR agonist can enhance the immune 
response triggered by cancer vaccines [116]. These have led to the design of clinical 
trials using TLR agonist such as CpG (ProMune) as adjuvant for anti tumour 
immunotherapy in non small cell lung carcinoma[117].  
There are a few mechanisms by which direct stimulation through TLR may produce 
significant anti-tumour activity. (1) Enhancement of innate immunity, which includes 
activation of NK cells, monocytes, macrophages and induction of cytokines such as 
IFN-γ and TNF-α. (2) Enhancement of T-cell immunity. Cytotoxic T-lymphocytes 
can be stimulated by antigens released from tumour cells killed by innate mechanism 
or by co-administered cytotoxic drugs. (3) Enhancement of cytotoxic antibody 
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function. Antibody-dependent effector functions can be enhanced by stimulation 
through TLR. (4) Induction of apoptosis in TLR-positive tumours.  
TLR ligands are increasingly used not only as an adjuvant to cancer therapy but also 
in cancer therapy directly. TLR7 agonist, Imiquimod, is currently approved for use in 
superficial basal cell carcinoma. There is also interest in the potential to complement 
such TLR agonist therapy with radiation or cytotoxic drugs. A combination of 
ProMune (TLR 9 agonist) with chemotherapy drugs increased response in first line 
chemotherapy in NSCLC [118]. Ampligen (a TLR3 agonist), is also now being tested 









Polyinosinic-polycytidilic acid (poly (I:C) was obtained from Invivogen and showed 
<0.0125 EU/mg endotoxin contamination. Phorbol 12-myristate 13-acetate (PMA) 
and ionomycin were obtained from Sigma-Aldrich,Singapore 
2.2 Patient Samples 
 
Gene expression and/or immunhistochemistry analysis were performed on core 
tumour from HCC patients. Samples were obtained with Ethics Committee approval 
from patients who underwent curative resection at the National Cancer Centre, 
Singapore, and Queen Mary Hospital, Hong Kong, between 1991-2009. 
2.3 Cell Isolation 
 
Peripheral Blood Mononuclear cells (PBMC) were derived from healthy donors by 
Ficoll/Hypaque density centrifugation (GE healthcare). NK cells were isolated by 
negative selection using a NK isolation kit (Miltenyl Biotech) according to the 
manufacturer’s instruction. The negative fractions (NK cells) were stained for FITC 
CD3, PE CD56, PE-Cy7 CD14 and APC CD19 to determine purity. The purity of NK 




2.4 Cell Culture 
 
HCC cell lines HepG2 and Huh7 were obtained from the American Type Culture; 
HCC cell lines SNU-475, SNU-449, SNU-387, SNU-386, SNU 182, SNU 423, SK-
Hep, Hep3B and PLC/PR5 were obtained from the Korean cell line bank. All cell 
lines except HepG2, Sk-Hep and Hep3b were cultured in RPMI 1640 (Invitrogen Life 
Technologies) supplemented with 10% FCS, 5% Pen/strep, 20mM Hepes, 1mM 
sodium pyruvate, L-Glutamine, MEM amino and non essential amino acids. The cells 
were maintained at 37oC in a humidified incubator with 5% CO2 in atmospheric air. 
Cells were sub-cultured every 3-4 days at a split ratio of 1:5. 
NK cells were cultured at 37oC, 5% CO2 in RPMI, 10% human serum and 5% 
pen/strep at a concentration of 4-5 million NK cells in 2ml media in 6 well plates. 
Recombinant IL-2 (R&D,Singapore) was added at a concentration of 50units/ml. NK 
cells were either unstimulated or activated with poly I:C at 50ug/ml for 24h. 
2.5 Total RNA Extraction and cDNA Synthesis 
 
Total RNA was isolated by Trizol (Invitrogen) in combination with Nucleospin RNA 
II (Macherey-Nagel). RNA concentration was assessed by Nanodrop. RNA was 
converted to cDNA using the Taqman Reverse Transcription reagent (Applied 
Biosystem) with the API thermacycler 2720 (Applied Biosystem) using the following 





2.6 Primer Design and quantitative PCR 
 
mRNA sequence was obtained from Emsebl. Primers were designed using Primer3 to 
obtain an aplicon size between 70 and 85bp. Primer specificity was checked by 
blasting the primer sequence into Aceview. Quantitative PCR was performed using 
iTAQ SYBR green Supermix with ROX (Bio-Rad Laboratories). Primers were used 
at a final concentration of 25nM. qPCR data were collected with the Mx3000P QPCR 
system (Stratagene). Relative levels of gene expression were calculated by 
normalisation to the housekeeping gene β-Actin using MxPro Software.  
2.7 Fluorescence-based Flow Cytometry  
 
Apoptotic cells was assesed by Annexin V-FITC (BD Pharmingen) and Topro 3 (final 
concentration 5nM) (Invitrogen) staining according to the manufacturer instructions 
and subsequent analysis on BD FACS Caliber. A total of 10,000 events were 
collected for each condition. Data analysis was done with FlowJo Software,Treestar, 
USA. 
2.8 Silencing of TLR3 using siRNA 
 
Transfection of TLR3 was done with the predesigned stealth select RNAi (Invitrogen). 
Cells were seeded in 6 well plates overnight. In each well, RNAi duplex was diluted 
in 250ul Opti-Mem® I medium without serum to a final concentration of 50nM and 
incubated for 5 mins at room temperature. 10ul of Lipofectamine TM 2000 was added 
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to 250ul Opti-Mem® and incubated for 5 mins. After that, the lipofectamine mixture 
was added to the RNAi duplex mixture and incubated for 20mins at room temperature 
to allow for the formation of complexes. After that the total 500ul RNAi –
Lipofectamine mixture was added to the HCC cells in R10 medium without 
antibiotics and 2% FCS to a total volume of 2ml per well. The plate was gently mixed 
and incubated for 6hrs at 37 oC in a humidified CO2 incubator after which qPCR and 
western blot analysis was carried out to validate the silencing of TLR3. This 
transfection was optimized using βeta-Actin siRNA (Invitrogen) to verify that the 
delivery was optimal. 
2.9 Cytotoxicity assay 
 
After stimulation with poly I:C, NK cells were cocultured with target cells (K562,  
ATCC or SNU 182, Korean cell bank) at the indicated Effector:Target ratio for 4h at 
37 oC, 5% CO2 .  Target cells were labeled using a DELFIA EuTDA-based 
cytotoxicity assay kit (Perkin-Elmer, Boston, MA) according to the manufacturer's 
instructions, with minor modifications. Briefly, 1 × 106  target cells/ml were loaded 
with 2.5ul of BATDA (bis-(acetoxymethyl)-2,2′:6′,2″-terpyrid-ine-6,6″-dicarboxylate) 
for 30 min at 37 °C, washed with culture media 4 times, and resuspended in the 
appropriate volume of culture media. 100 μl culture medium with the target cells 
were added in a round-bottom 96-well plate. The NK cells were then resuspended in 
RPMI and 100ul of NK cells were added to the target cells at the indicated E:T ratios. 
The plate was centrifuged for 5 min at 500 × g and then incubated for 4 h at 37 °C. 
DELFIA europium solution was added to cells and then fluorescence was measured 
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on an EnVision instrument (Perkin-Elmer). The percentage of specific cytotoxicity 
was calculated as (experimental release − spontaneous release)/(maximum 
release − spontaneous release) × 100. Spontaneous release was determined by 
incubating the targets with media instead of effector cells, and maximum release was 
determined by incubating target cells with 100ul of media with 10% triton X. 100ul 
of the media from the last wash of the target cells were also taken for background 
reading. 
2.10 Immunohistochemistry  
 
Paraffin-embedded tissue sections which include the tumour, peri-tumour and non-
tumour liver tissues were obtained from a cohort of HCC patients for analyses. Four 
µm sections were deparaffinized, hydrated and then subjected to antigen retrieval at 
95oC for 30 mins at either pH 6 or 9. Blocking of endogenous peroxidase was done 
with 1.5% of hydrogen peroxide for 30mins at room temperature. Sections were then 
blocked with 10% normal goat serum for 1 hr at room temperature. Following that, 
primary antibody was added at the indicated dilutions. Rabbit polyclonal anti-Ki-67 
was used at 1: 50 ( Norvus Biologics) and rabbit polyclonal anti-activated caspase 3 
was used at 1: 200 (Promega). Incubate with secondary antibody at room temperature 
for 30mins. Detection was done using DakoCytomation Envision+ HRP system 
(Vector Laboratories). Slides were then counter stain with Haematoxylin for 5 
seconds before dehydration and mounting with a non-aqueous mounting agent. 
For double immunhistochemistry, sections were treated similarly as above with the 
addition of an avidin block and biotin block. Detection was done with AEC substrate 
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kit for Peroxidase (Vector Laboratories) for red staining. Immunostaining for those 
with an alkaline phosphatase-conjugated secondary antibody was detected by alkaline 
phosphatase substrate kit with blue staining (Vector Laboratories). Mouse 
monoclonal TLR3 (Imgenex) was used at a dilution of 1: 50. Rabbit polyclonal CD3 
(Dako) was used at a dilution of 1:80. Rabbit polyclonal CD20 (Norvus Biologics) 
was used at a dilution of 1:50. Rabbit polyclonal GZB (Abcam) was used at a dilution 
of 1:150. Density of cells that was required for quantification, counting was done 
from random photos of 5-10 tumour areas at 100x magnification and the mean 
number is taken per patient. 
2.11 ELISA 
 
Plates were coated with the purified anti-IFN-γ antibody (Biolegend) at a final 
concentration of 2ug/ml in 50ul per well. Samples are added diluted with blocking 
solution and added in a 50ul per well. Detection is done with the biotin IFN-γ 
antibody with a final concentration of 0.5ug/ml in 50ul per well. Following this, 
streptavidin-conjugated HRP is added at a 1:250 dilution before incubating in the 
dark for 30mins. TMB (3,3′,5,5′-tetramethylbenzidine)  substrate is added and left in 
the dark to develop to a blue colour. A 2M H2SO4 is then added to stop the reaction. 







2.12 Statistical Analysis 
 
Kaplan-Meier univariate survival analysis was performed on patients with GraphPad 
Prism. Gene expression values were categorized as either “Low” or “High” based on 
the median value. Patients surviving at the last follow-up and patients deceased for 








3.1 TLR3 expression within tumours correlates with prolonged HCC patient 
survival. 
 
We have previously measured the expression of 49 immune genes using quantitative 
RT-PCR from core tumour and adjacent non tumour liver tissues taken from resected 
HCC patients (Singapore cohort). Our results indicate a high degree of heterogeneity 
in immune related profile across the different tumour samples [46]. We therefore 
sought to analyze if the expression level of these genes is associated to clinical 
etiology or endpoints. By differential gene expression analysis, we found no 
significant association between the immune microenvironment and the tumour 
etiology (HBV, non viral), stage or grade.  
We then examined whether the expression of these genes within tumour is associated 
with prognosis. Kaplan-Meier analysis was done on 2 independent cohorts of patients, 
one from Singapore and the other from Hong Kong. Both cohorts of patients display 
similar characteristic for clinical and demographics parameters used in HCC, except 
for stage and alpha-fetal protein concentration (Table 2). The Singapore cohort has 
more patients in stage 1 (57%) and less patients in stage 2, 3 and 4 (43%) compared 
to Hong Kong which has less patients in stage 1 (5%) and more patients in stage 2, 3, 
and 4 (95%). 
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Variables SG (n=61) HK (n=56) p-value
Sex, F/M Number 
(percent)
7/54(11/89) 8/49 (14/86) ns*
Age, years Median 
(Range)
59 (31-84) 57 (28-82) ns@
Race, Chinese/Others Number 
(percent)





13/46 (21/75) 5/50 (9/88) ns*
Grade, 1+2/ 3+4 Number 
(percent)
33/25 (54/41) 29/26 (51/46) ns*
Stage, 1/ 2+3+4 Number 
(percent)
35/26 (57/43) 3/54 (5/95) < 0.0001*
α-fetoprotein, ng/ml Median 
(Range)
25 (2->70,700) 327 (2-468,600) 0.0015@
Tumor size, cm Median 
(Range)
6 (0.7-20) 6 (2-27) ns@
Survival, years Median 
(Range)
3.94 (0.02-11.2) 6.1 (0.03-16.31) ns#
 
Table 2. Comparison of clinical and demographic characteristics of HCC patients from Singapore and 
Hong Kong. 
 * Ficher’s exact test , # Kaplan-Meier , @ Mann-Whitney .  
 
Our results indicate that patients with higher expression of TLR3 have a significantly 
longer overall survival compared to patients expressing lower expression of TLR3. 
This is observed in Singapore (Figure 7A, p= 0.05, hazard ratio 2.4) as well as Hong 
Kong cohort of patients (Figure 7A, p=0.02, hazard ratio 2.4). To find out if this is 
also true at the protein level, immunohistochemistry (IHC) was done on 20 HCC 
patients from each cohort. The gene expression of TLR3 is found to be correlated with 
the density of TLR3+ cells by IHC in the Singapore (Figure 7B, p=0.003, r= 0.63) 
and Hong Kong patients (p=0.002, r= 0.64). The TLR3 protein expression is 
correlated with HCC patient survival (Figure 7C), indicating that those with high 
number of TLR3+ cells  have longer survival compared with patients with lower 
numbers of TLR3-expressing cells. Indeed, similar to the results we observed in the 
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gene expression of TLR3, a Kaplan Meier analysis on patients with high level of 
TLR3 protein expression showed prolonged survival compared to those with low 
TLR3 protein expression (Figure 7D, p=0.0001, hazard ratio 17.73 for Singapore and 



















Figure 7. TLR3 expression within tumours correlates with prolonged HCC patient survival 
 (A) Kaplan-Meier survival graphs of patients with high TLR3 (full line) and low TLR3 (dotted line) gene 
expression.  TLR3 expression is positively associated with patient survival in 61 Singapore patients and 57 Hong 
Kong patients.(B) Correlation between TLR3 gene expression  and TLR3 protein as measured by qRT-PCR and   
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Figure 7. TLR3 expression within tumours correlates with longer HCC patient survival 
TLR3 protein expression is positively associated with HCC patient survival. (C). Correlation between TLR3 
density (IHC) and survival of HCC patients. (D)Kaplan Meier survival graphs of HCC patients with high TLR3 




3.2 TLR3 is expressed by cancer cells and NK cells. 
 
Previously, to determine which cells express TLR3 and is associated with longer 
survival, we compared their mRNA level in (1) core tumour tissues from HCC 
patients,(2) leucocytes purified from HCC tumours and (3) HCC tumour cell lines. 
TLR3 was lower in tumour leucocytes compared to core tumour and the level for the 
infiltrating leucocytes was approximately similar to HCC cell lines (not enriched in 
the TILs). This indicates that TLR3 could come from both the leucocytes and the 
tumour cells [46].  
In the resected tumours of HCC patients, TLR3 is detected by immunohistochemistry 
in both cancer cells and infiltrating immune cells. TLR3 staining was observed in the 
cytoplasm of cancer cells, as reported for human dendritic cells (Figure 8A) [58]. 
TLR3 expression is usually clustered in certain areas of the tumours. This could be 
due to a local stimulation of TLR3 by its ligand or alternatively a somatic mutation of 
the tumour cells.  
Immunohistochemistry staining of TLR3 also stains for infiltrating immune cells. 
These TLR3-positive cells are usually round cells found in the spaces between the 
tumour areas. To further refine the identity of TLR3-expressing cells within the 
tumours, double immunohistochemistry was done with various immune cell markers 
such as CD3, CD8, CD20 and granzyme B (GZB). We have also previously stained 
for dendritic cells with DC-lamp but very few cells were detected in the tumour area 
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[46]. Representative IHC staining for the various markers is shown in Figure 8B. 
Double IHC does not show co-localisation of TLR3 with CD3 and CD20 cells but 
with GZB+ cells. Although both NK and CD8 T cells secrete GZB when activated, 
we found little co-staining of TLR3 with CD8 (data not shown) or CD3 (Figure 8B), 
hence showing that NK cells, and not T cells are the main immune cells that 
expresses TLR3 in the tumour. Therefore, TLR3 staining observed in both the tumour 
and NK cells confirmed our earlier gene expression data that both tumour and 





3.3 TLR3 expressed by both the cancer cells and NK cells are associated with 
longer patients survival in 2 cohorts. 
 
The density of TLR3-positive cells (a combination of tumour and NK cells) is 
significantly correlated with survival of HCC patients. To determine whether TLR3 
expression by cancer cells or NK cells is responsible for this association, we 
performed separate analysis of TLR3 expression coming from NK and cancer cells. 
Kaplan Meier analysis of TLR3-positive NK cells shows that HCC patients with high 
expression of TLR3, survive longer than those with low expression of TLR3 in their 
NK cells (Figure 9A, SG, p=0.01, hazard ratio = 6.2 and HK, p=0.001, hazard ratio 
4.4). Similarly in the TLR3 expressing tumours, patients with high TLR3 expression 
in the tumours survive longer than those with low TLR3 (Figure 9B). These results 
suggest that TLR3 in both cancer cells and NK cells may contributes to the survival 
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Figure 8.  TLR3 is expressed by both cancer cells and NK cells.  
(A) Expression of TLR3 by cancer cells. Representative picture showing expression of TLR3 (stained in red) in 
the cancer cells of HCC patient. (B) Expression of TLR3 by NK cells. Representative picture showing expression 
of TLR3 in NK cells in HCC patient. TLR3 (in red) is not found in CD3 or CD20 cells but in GZB positive cells 






















Figure 9. TLR3 expressed by both the tumour cells and NK cells is associated with prolonged patient 
survival. 
(A) Kaplan Meier survival graphs of HCC patients with high TLR3 density (dotted line) and low TLR3 density 
(full line) expression in NK cells. (B) Kaplan Meier survival graphs of HCC patients with high TLR3 density 
(dotted line) and low TLR3 density (full line) expression in tumours. 
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3.4 HCC cells express functional TLR3 and triggering TLR3 augments its 
expression. 
 
Since the expression of TLR3 by cancer cells in HCC patients is associated with 
prolonged patient’s survival, we wanted to evaluate in vitro the functional 
consequences of TLR3 expression by HCC cells.  We identified HCC cell lines with 
varying levels of endogenous gene expression of TLR3 by qRT-PCR (Figure 10A). 
Two cell lines were chosen for further analysis: the SNU 182 cell line which displays 
a strong expression of TLR3 and PLC/PR5 which has no expression of TLR3.  
To activate TLR3 signaling, we used poly I:C, a commonly used synthetic dsRNA 
which is a ligand for TLR3 [119]. SNU 182 cell line was stimulated with increasing 
concentration of poly I:C:  a dose dependent increase of TLR3 mRNA was observed 
as shown in Figure 10B. TLR3 expression is significantly enhanced at a concentration 
of 50μg/ml (p<0.005) and 100μg/ml (p<0.0005) when compared with untreated 
control. This suggests that TLR3 expressed by HCC cell line is functional and that 
triggering TLR3 augments its own expression. 
To determine the kinetics of TLR3 gene regulation, we stimulated SNU 182 cells with 
50μg/ml poly I:C and measured TLR3 gene expression at 3h, 6h, 12h, 24h, 48h and 
72h.  TLR3 gene expression increases and peaks at 6h. mRNA expression at 6h is 
approximately 10 fold compared to its non stimulated control. This is followed by a 
decrease in TLR3 gene expression to 8 fold for 24h (p< 0.005), 4 fold at 48h (p<0.005) 
and finally a plateau for 72h (p<0.05). This is still significantly higher than untreated 
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cells. These data indicate that gene expression of TLR3 mRNA is an early event 
which peaks by 6h.  
The same stimulation was done on PLC/PR5, and kinetics of TLR3 gene expression 
was measured. As expected, no significant increase of TLR3 mRNA can be seen even 
when the cells are stimulated for 72h (Figure 10C), suggesting that a basal expression 









Time after stimulation Time after stimulation  
Figure 10.TLR3 in HCC cells is functional and triggering TLR3 with dsRNA augments its own expression.   
(A)TLR3 mRNA is measured in 11 HCC cell lines. SNU 182, which display a strong expression of TLR3 and 
PLC/PR5 which have no TLR3 expression are used for subsequent analysis. (B) Dose dependent gene expression 
of TLR3 is observed. SNU 182 cells are stimulated without or with increasing concentration of poly I:C 0.5μg/ml, 
5μg/ml, 50μg/ml and 100μg/ml and TLR3 mRNA measured.  (C) TLR3 gene expression peaks at 6h. SNU 182 
cells are stimulated either  without (empty squares) or with (filled squares) 50μg/ml polyI:C  for 3h, 6h, 12h 
24h,48h and 72h and TLR3 mRNA measured. Right panel shows stimulation of poly I:C with PLC/PR5 cells 
which are cells with no TLR3 expression. Star indicates a statistical difference from respective controls (p<0.05) 
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3.5 DsRNA triggers cell death in HCC cells that express TLR3. 
 
To gain insight on the mechanism by which TLR3 in cancer cells could be associated 
with HCC patient survival, we measured cancer cell apoptosis after activating TLR3 
with poly I:C. Apoptosis was quantified by flow cytometry using annexin V (early 
apoptotic marker) and TO-PRO-3 (late apoptotic marker) as shown in Figure 11A. 
The number of dead cells increased after stimulation with poly I:C at the indicated 
timepoints. A dose-dependent effect on the percentage of dead cells is seen by 
increasing the dosage of poly I:C (Figure 11B). A dose as low as 5μg/ml of poly I:C 
is sufficient to induce cell death of about 18% and the percentage of dead cells 
increases to reach approximately 25% as the dosage increases to 50μg/ml and reaches 
to about 40% of dead cells with a poly I:C dose of 100μg/ml (p<0.05).  This indicates 
that TLR3 signaling leads to cell death in HCC cells. Similar to the dose-dependent 
effect in TLR3 gene expression, a dose-dependent increase in percentage of dead cells 
shows that this functional effect of TLR3 is dependent on its expression in the cancer 
cells. 
Kinetics studies show a significant increase in dead cells which reaches 40% by 24h 
(Figure 11C). However the number of apoptotic cells remains the same even when the 
cells are stimulated for 72h. This partial response to poly I:C suggest that not all 
cancer cells express TLR3 and only the cells that express it will die.  We verified the 
percentage of dead cells with that of recovered cells. The percentage of recovered 
cells increases with time for the untreated cells. On the other hand, for cells treated 
with poly I:C, the percentage of recovered cells decreases from 0 to 24h and then 
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increases till 72h. The increase in treated cells is not as fast as untreated cells, 
suggesting that cells treated with poly I:C are proliferating at a slower rate (Figure 
11D).  This suggests that besides triggering apoptosis, TLR3 could also inhibit cancer 
cell proliferation.  
Other TLR ligands such as CpG (50μg/ml), TLR9 ligand, and LPS (20μg/ml), TLR4 
ligand were cultured with SNU 182 for 24h and no significant increase in cell death 
was seen (27% in CpG compared to 21% in untreated cells, Figure 11F). dsRNA was 
also cultured with the  TLR3-negative cell line PLC/PR5 for up to 72h and there was 
no increase in cell death compared to control at each of the indicated timepoints 
(Figure 11G). Collectively, these results demonstrate that signaling through TLR3 but 
not other TLRs, induces cell death in TLR3-positive HCC cells 
Other HCC cell lines such as SNU 449 and Hep3B were also stimulated with poly I:C 
but there was no significant increase in cell death up to 72h. The mRNA levels of 
these cell lines did not reveal an upregulation of TLR3 when stimulated with dsRNA 
(data not shown), showing that an increase in TLR3 expression is needed before cell 





























Figure 11.  DsRNA stimulation on TLR3-positive HCC cell can lead to cell death.  
(A) Cell death is observed with poly I:C. Representative FACS characterization of dead cells with annexin V and 
TO-PRO-3 staining for SNU 182 cell line stimulated with poly I:C for 24h, 48h and 72h. Gated cells represent 
dead cells expressed as a percentage of the total cells. (B) Dose-dependent increase in cell death is observed. SNU 
182 cells are stimulated with increasing doses without or with poly I:C, 0.5μg/ml, 5μg/ml, 50μg/ml and 100μg/ml. 
Percentage of dead cells is expressed as TO-PR-3+ cells.  (C) Poly I:C stimulated cells have increased percentage 
of dead cells compared to untreated but remains the same till 72h. SNU 182 cells are stimulated either without 
(empty square) or with (filled square) with 50ug/ml poly I:C  for 24h, 48h and 72h.  (D) Percentage of recovered 
cells in poly I:C treated cells(filled square) is not comparable to non-treated cells (empty square). The percentage 
of recovered cells is calculated on the number of viable cells at the end of the timepoint to the number of seeded 





















Figure 11. DsRNA stimulation on TLR3-positive HCC cells lead to cell death.  
(E)Stimulation of TLR3 (+) cell line, SNU 182 with other TLR ligand such as CpG, a TLR9 ligand, (50ug/ml) and 
LPS, a TLR4 ligand, (20ug/ml) does not cause significant cell death compared to untreated cells at 24h. (F) 
Stimulation of TLR3 (-) cell line PLC/PR5 with poly I:C for 24h does not lead to cell death. 
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3.6 DsRNA induced tumour cell death is mediated by TLR3. 
 
Several receptors have been described to bind to or mediate the effects of dsRNA in 
the cell besides TLR3, such as RIG1 or MDA5. Because TLR3 gene expression and 
effect of cell death are both dosage-dependent, we next asked whether the 
proapoptotic effect of poly I:C in these cells is indeed mediated by TLR3. To confirm 
this, we did a transient knock-down of TLR3 gene expression. The expression was 
effectively knocked down (more than 90% in Figure 12A) as compared to the 
scrambled control in SNU 182 and the knock-down persisted up to 120hrs. Because 
poly I:C can upregulate TLR3 expression, we measured the TLR3 expression after 
dsRNA stimulation on these knock downed cells. Again TLR3 expression was 
effectively knock downed (more than 90%) compared to the scrambled control even 
when poly I:C is added (Figure 12A).  
Flow cytometry characterization of the TLR3 knockdown cells stimulated with or 
without poly I:C and stained for annexin V and Torpo 3 are shown in Figure 12B. 
Without poly I:C stimulation, the percentage of dead cells for the TLR3 knock down 
is approximately 15% (Figure 12C) and this is similar to the percentage of dead cells 
in the scrambled control. However when TLR3 is triggered, the percentage of dead 
cells in the scrambled control increases to 40%. The percentage of dead cells drops to 
27% in the TLR3 knock-downed, showing that the increase in dead cells is inhibited 
partially by 50% by TLR3 (Figure 12C, p<0.005). This clearly demonstrates that 




As the percentage of recovered cells is less in the scrambled control compared to the 
TLR3 knock down (100% compared to 180%, Figure 12D), it suggest that TLR3 



























Figure 12. TLR3 knock down inhibits poly I:C-induced cell death. 
(A) Gene expression of TLR3 is effectively knocked down. TLR3 gene expression is measured after transfecting 
the cells with TLR3 or scrambled siRNA for 24h. Gene expression of TLR3 was also measured after transfecting 
with siRNA for 24h and stimulating the cells for poly I:C for 24h (B) Less cell death is seen when the TLR3 
knock down cells are stimulated with poly I:C. Cells were transfected with scrambled or TLR3 siRNA (100pmol) 
for 24h before changing media and after 72h, stimulating the same cells without or with poly I:C (50μg/ml) for 
24h. Representative FACS plot of % of dead cells (Annexin V and TO-PRO-3+ cells) with TLR3 and scrambled 










Figure 12. TLR3 knock down inhibits poly I:C induced cell death. 
(C) Percentage of dead cells decreases in TLR3 knock down cells compared to scrambled transfected 
cells when poly I:C is added. Percentage of dead cells is measured after TLR3 knock down (white bars) 
with or without poly I:C. (D) The percentage of recovered cells is less in the scrambled cells compared 
to TLR3 knock down cells. The percentage of recovered cells is calculated on the number of viable 




3.7 Activated NK cells increases with dsRNA stimulation. 
 
In our earlier figures, we show that TLR3 is found in NK cells and positively 
associated with HCC patient survival. To further elucidate the mechanism by which 
TLR3 expression in NK cells can be associated with longer HCC survival, we 
isolated NK cells from healthy PBMC and stimulated them with poly I:C. 
As TLR3 is known to be expressed by dendritic cells, monocytes and epithelial cells 
[119-121], it is important that the isolation of NK cells from human PBMC be free of 
other contaminating immune cells. As shown in Figure 13A, the purity of isolated NK 
cells was always more than 90%. To confirm that isolated NK cells were free from 
other contaminating cells, CD3, CD14 and CD19 markers were also used to assess 
the percentage of cells in PBMC and NK fractions. In the PBMC, there were 46% of 
CD3 cells compared to 0.7% of CD3 in the NK cells. For CD14 monocytes, there was 
about 35% in the PBMC compared to 0.9% in the NK cells. Finally the NK cells were 
free of CD19 compared to about 36% in the PBMC. This demonstrate that most of the 
NK cells were free from CD3 T cells, CD14 monocytes and also CD19 B cells, 
leaving a highly enriched NK population of approximately 98% (Figure 13A).  
After 24h culture with poly I:C and IL-2, the activation status of NK cells was 
assessed by staining with CD69. CD69 is a cell surface marker that has been shown to 
be upregulated on NK cells after activation by cytokines such as IL-2, IL-12 and IFN-
α [122]. Figure 13B shows a representative flow cytometry analysis of dsRNA-
stimulated NK cells with an increased percentage of activated NK cells compared to 





























Figure 13. NK cells are activated by poly I:C stimulation.  
(A) NK cells are free from other immune cells. NK cells are isolated from human PBMC and the purity of NK 
cells is compared with PBMC. Both PBMC and NK are stained with CD56, CD14 and CD19 to check the purity 
of isolated NK cells. (B) NK cells are activated by poly I:C at 24h. NK cells are stimulated without or with 
50μg/ml poly I:C and stained for CD56 and CD69. Data shown are the flow cytometry representation of PBMC 
and NK cells. 
62 
 
3.8 NK cells have higher TLR3 expression compared to HCC cells and dsRNA    
can increase the expression of TLR3 in NK cells. 
 
As we have found that NK cells express TLR3 in HCC patients, we wanted to compare 
the expression of endogenous TLR3 in peripheral NK and cancer cells, we measured 
TLR3 mRNA and observed a higher TLR3 expression in NK compared to HCC cells 
(Figure 14A). This might suggest that TLR3+ NK cells may have a stronger effect 
compared to tumour cells when stimulated.  
We have previously shown that TLR3 expression was lower in the tumour-infiltrating 
leukocytes and HCC cell lines compared to the core tumour [46]. Hence its expression in 
immune cells would have to be upregulated to affect the overall level of expression in 
patients with long survival. Earlier, we show that TLR3 can upregulate its expression in 
TLR3-positive HCC cells. Similarly, when TLR3 signaling is activated with dsRNA in 
NK cells, the expression of TLR3 is increased (4 fold compared to control, Figure 14B). 
This demonstrates that NK cells express TLR3 and TLR3 expression is augmented upon 




























Figure 14. Poly I:C enhances NK cell activity and cell-mediated cytotoxicity  
(A) NK cells express higher TLR3 mRNA compared to peripheral NK cells. Relative gene expression of TLR3 in 
HCC cell lines compared to NK cells. (B) Poly I:C increase TLR3 and NK cells effector gene expression (C) Poly 
I:C increase IFN-γ secretion by NK cells by 24hrs (D) Poly I:C stimulation enhances NK cell-mediated 




3.9 DsRNA augments the expression of NK cells effector molecules and increases 
cell mediated cytotoxicity towards HCC cells. 
 
To investigate functional effects of poly I:C on NK cell function, we examined the 
production of cytokines by purified NK cells after stimulation with poly I:C for 24h. 
Treatment with poly I:C could upregulate the gene expression of IFN-γ up to 4 fold 
(Figure 14B). The upregulation of IFN-γ protein is seen in 5 out of 6 donors, with a 
median of 300pg/ml for treated NK cells compared to 70pg/ml for untreated NK cells 
(Figure 14C). Other cytokines that have been reported to be increased with activated NK 
cells such as TNF-α, IL-6 and IFN-α did not show an increase in gene expression in 
either of the donors measured. We further investigated gene expression of cytoplamsic 
granules such as granzyme B and perforin that are responsible for NK cell cytotoxicity.  
Granzyme B shows a 4 fold increase while perforin has a lesser increase of about 1.5 fold. 
The NK receptor, NKp30, is not upregulated in the treated NK cells.  
NK cells, either untreated or stimulated with poly I:C were co-cultured at various effector 
– to-target ratios and NK cell-mediated killing of the HCC cell line SNU 182 was 
analysed. 4 times less NK cells were needed to lyse HCC cells when NK cells are treated 
with poly I:C. (Figure 14D). This clearly demonstrates that dsRNA can activate NK cells 
to upregulate IFN-γ secretion as well as granzyme B and perforin which are cytotoxic 
granules. DsRNA activated NK cells can also increase cell-mediated cytotoxicity towards 




3.10 TLR3 expression in both cancer and NK cells is associated with tumour 
cells apoptosis and non-proliferating tumours. 
 
In vitro, we see that TLR3 expression in both cancer cell and NK cell leads to cancer 
cell death and apoptosis. More importantly, TLR3 in cancer and NK cells is 
associated with patient survival. Therefore, to gain insight into the mechanism by 
which the 2 compartments could control tumour progression, we evaluated cancer cell 
apoptosis and proliferation. Representative immunohistochemistry staining for 
activated caspase-3 (marker of apoptosis) and Ki-67 (marker of proliferation) are 
shown in Figure 15A and B respectively. HCC patient survival is correlated 
negatively with the density of Ki-67+ and positively with that of activated-caspase 3+ 
cancer cells (Figure 15C).  We found that the density of CD8+T cells [46] and 
CD56+ NK cells (Figure 15D) correlates positively with that of apoptotic cancer cells 
and negatively with the number of proliferating cancer cells. Hence NK cells, one of 
the main proliferating lymphocytes in HCC tumour may be controlling tumour 
progression.  
To further confirm that the expression of TLR3 in cancer cells and NK cells is 
associated with tumour apoptosis and proliferation, we show that the density of 
TLR3+ NK cells correlates negatively with Ki-67+ and positively with activated-
caspase-3+ cancer cells (Figure 15E). Similarly, TLR3 expression in the cancer cells 
correlates negatively with proliferating cells and positively with apoptotic cells 
(Figure 15F). Altogether, our results indicate that the expression of TLR3 in both NK 
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Figure 15. TLR3 is associated with tumour cell apoptosis and non-proliferating tumours . 
(A) Left panel show few activated-caspase-3+ cells (red) in a short survival patient (0.45 years, bar=50μm) while 
right panal shows numerous activated caspase 3+ cells in a long survival patient (3.26 years, bar=50μm) (B) Left 
panel show few Ki-67+ cells (red) in a long survival patient (3.26 years, bar =50μm) while right panel shows 









Figure 15. TLR3 is associated with tumour cell apoptosis and non proliferating tumours . 
(C) Positive correlation between patient survival and density of activated-caspase-3+ cancer cells and negative 
correlation between patient survival and density of Ki-67+ cancer cells in 8 HCC patients. (D) Positive correlation 
between CD56 NK cells and density of activated caspase-3+ cells and negative correlation between CD56 NK 
cells and density of Ki-67+ cells in 8 HCC patients. (E) Positive correlation between TLR3+ NK cells and density 
of activated-caspase-3+ (n=19) cells and negative correlation between TLR3+ NK cells and density of Ki-67+ cell 
(n=9).  (F) Positive correlation between TLR3+ cancer cells and density activated-caspase 3+ cells and negative 




3.11 TLR3 expression decreases in higher grade tumours and more advanced 
stage patients 
 
To investigate if TLR3 expression is linked to the progression of the disease, we 
looked at the TLR3 gene expression levels in tumour of different grades as well as the 
in the early and late stages of HCC. TLR3 mRNA levels are significantly higher in 
patients that have low grade tumours compared to those with high grade tumours 
(Figure 16A). Similar to the mRNA results, the density of TLR3-positive cells 
decreases in higher grade tumours.  
When HCC patients are separated into stage 1 and 2 (early stage) versus stage 3 and 4 
(late stage), we see that TLR3 mRNA levels are significantly higher in the early stage 
compared to the later stage of HCC (Figure 16B). Similar to the mRNA results, the 
density of TLR3+ cells decreases in more advanced stage patients.  These data shows 
that TLR3 expression decreases with the advancement of the disease and suggests 












Figure 16.TLR3 expression decreases in higher grade and more advanced stage patients. 
 (A) TLR3 decreases in higher grade tumours. Gene expression of TLR3 (left panel, n= 113) and no of TLR3+ 
cells (right panel, n=39) in HCC patients with low and high grade tumours. (B) TLR3 decreases in more advance 
stage patients. Gene expression of TLR3 (left panel, n=137) and no of TLR3+ cells (right panel, n=39) in early 
stage and late stage HCC patients.  
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4. DISCUSSION  
 
4.1 The expression of TLR3 is associated with prolonged HCC patient survival 
 
HCC is the fifth most common cancer worldwide and has a high mortality rate with 
limited effective treatment options. This study shows for the first time that an 
enhanced expression of TLR3 is associated with prolonged survival of HCC patients. 
This finding is somehow reminiscent of a previous study on breast cancer showing 
that only patients with TLR3 positive tumours benefited from TLR3 agonist (poly 
A:U) treatment and showed increased overall survival [73]. However, in HCC 
patients, we found that even in the absence of treatment with TLR3 agonists, 
endogenous expression of TLR3 is associated with a prolonged survival. Interestingly 
in recent data from Budhu et al [44], we noticed that TLR3 is one of the genes 
downregulated in the immune genes signature associated with metastatic-inclined 
hepatic. HCC patients with metastatic-inclined tissues were associated with lower 
survival. This suggests that TLR3 may be associated with longer patient survival.  
This further supports our findings that endogenous expression of TLR3 is positively 






4.2 What drives intratumoral expression of TLR3? 
 
TLR3 is expressed in both NK cells and cancer cells and expression in both 
compartments correlates with survival. TLR3 overexpression could be linked to (1) 
genetic polymorphism (2) previous treatment for chronic liver disease before the 
development of HCC (3) somatic mutation or (4) high concentration of its own ligand 
(dsRNA).  
Although TLR3 gene polymorphism has been described, there is no report that 
suggests TLR3 polymorphism can affect its expression level. While two TLR3 gene 
polymorphisms have been described to affect resistance to HCV infections, none of 
the two SNP was associated with the clinical parameters of disease progression in 
chronic HCV. This suggests that polymorphisms of TLR3 gene do not play a role in 
disease progression after a chronic situation is established. None of the two TLR3 
SNP were associated with TLR3 gene expression in PBMC [123]. In addition, our 
observation of clusters of TLR3-positive cells in certain parts of the tumour and not in 
other parts suggests that TLR3 upregulation might be a localized effect, possibly 
linked to the presence of DAMPs released. 
As most of the HCC patients had underlying chronic disease such as HBV before the 
development of HCC, we wondered if the expression of TLR3 could be due to 
previous treatment regimen, such as IFN-α therapy. Once again, however the 
observation of clusters of TLR3 in certain parts of the tumour and not in other parts of 
the same section of tumour, does not make this a likely possibility. 
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We also asked if somatic mutation such as the loss or gain of certain genes could 
affect the expression of TLR3. Although there has been a report on how p53 
positively regulates TLR3 expression in human epithelial cell lines [124], we do not 
think somatic mutation could be the reason for the increase in TLR3 expression. This 
is because most tumours usually lose p53 and hence result in a decrease in TLR3 
expression instead.  Furthermore we also observed a correlation between TLR3+ 
cancer cells and TLR3+ NK cells. The expression of TLR3 in NK cells refutes the 
possibility of somatic mutation as a loss or gain of genes in the cancer cells is 
unlikely to affect expression of TLR3 in the NK cells. Instead we postulate that a 
more likely mechanism would be the presence of TLR3 ligands which could be 
increasing the expression of TLR3 in both compartments. 
We therefore propose that the key event driving the expression of TLR3 is the 
presence of its own ligand (dsRNA). Although opportunistic infections may provide 
viral intermediates such as dsRNA in its process of replication, we found no 
significant association between the immune microenvironment and tumour etiology 
(HBV, HCV and non-viral). A more likely ligand would be endogenous danger 
signals that are generated from areas of tumour necrosis. DAMPs that are released 
from stressed or damaged tissue can signal through TLR. For example, HMGB1 is an 
established ligand for TLR4 [125]. Recent studies have shown that RNA from 
damaged tissues can serve as ligand for TLR3[50,51]. In an inflammatory 
situation,release of such endogenous ligands, from dead or dying cells are not 
uncommon. TLR3 has been shown to be an endogenous sensor of tissue necrosis 
during acute inflammatory events by detecting endogenous hairpin RNA [52]. Areas 
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of necrosis were abundant in the tumour areas that we analysed. This is consistent 
with our suggestion that dsRNA present in the tumour microenvironment upregulates 
the expression of TLR3 in tumours and NK cells, which in turn, control the 
progression of the tumours. Such a mechanism would explain the association between 





4.3 Possible mechanisms to explain the association of TLR3 with prolonged 
HCC patient survival 
 
Our results show that TLR3 expression in both cancer cells and NK cells is associated 
with prolonged HCC patient survival. This suggests that increasing the expression of 
TLR3 in either or both compartments could result in some mechanism to control 
tumour progression.  
In vitro, we showed that stimulation of endogenously expressed TLR3 in HCC cancer 
cells leads to its increased expression and subsequently to cell death. Stimulation of 
TLR3 may also inhibit tumour cell proliferation. These findings are consistent with 
our in vivo data which shows an inverse correlation between the expression of TLR3 
by cancer cells and NK cells on one hand and the proliferation of cancer cells on the 
other hand. Therefore, one of the mechanisms by which TLR3 expression in cancer 
cells may control tumour progression could be by induction of cancer cell death or 
inhibition of proliferation.  
When cancer cells die, more dsRNA is released, providing more ligands for TLR3 
thus increasing its expression. In support of this mechanism, we found a positive 
correlation between the expression of TLR3 (in both cancer and NK cells) and the 
number of caspase-3+ cells. This can also affect TLR3+ NK cells, and probably more 
so than cancer cells because the expression of TLR3 in peripheral NK cells is much 
higher than that by HCC cancer cells.  
NK cells are abundant among the liver lymphocytes and play an important role in first 
line innate defense against viral infection and tumour transformation. [81]. The 
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importance of NK cells during HBV and HCV is well established [102,126-128]. It 
has also been speculated that NK cells play a role in anti-tumour activity in HCC 
[107,108]. However the mechanism by which NK cells are recruited or activated in 
the liver remains largely unknown. In this study, we show that peripheral NK cells 
express TLR3, at a level much higher than HCC cells. Stimulation of TLR3 on NK 
cells leads to an increase in TLR3 expression and effector molecules such as 
granzyme B, perforin and IFN-γ. Although increased cytotoxicity towards NK 
sensitive cell lines after TLR3 signaling was already reported [63,64,111], our results 
show for the first time that direct activation of NK cells with dsRNA lead to an 
increase in cytotoxicity towards HCC cells. Hence, another mechanism by which 
TLR3+ NK cells might control tumour progression is by increased cytotoxicity 
towards HCC, most probably through increased production of effector molecules. 
We postulate that NK cells may kill HCC cells through the release of its effector 
molecules. In the mouse liver environment, we can see how the effector molecules 
secreted by activated NK cells can have increased cytotoxicity.  Murine NK cells can 
control the growth of liver cells in inflammatory situations such as that of liver injury. 
NK cells that are activated by poly I:C, may kill hepatocytes by upregulating TRAIL 
or/and granzyme [129,130]. Therefore it is possible that NK exert its cytotoxic effect 
through its effector molecules  
 Besides release of effector molecules, another mechanism that NK cells can kill HCC 
cells is by the upregulation of NK cell activating ligands. In the mouse liver, NK cells 
can  kill senescence-activated hepatic stellate cells that have increased expression of 
77 
 
NK cell activating ligands [86]. Hence NK cells cytotoxicity towards HCC tumours 
could be increased by senescence-activated HCC tumours that have increased the 
expression of NK cell activating ligands. 
One of the main functions of NK cells involves release of cytokines such as IFN-γ. 
IFN-γ inhibits proliferation through a STAT1-dependent mechanism, which 
subsequently leads to cell cycle arrest and apoptosis [86]. Hence another mechanism 
by which TLR3 expression in NK cells can control tumour progression could be the 
release of cytokines by NK cells. In our model, dsRNA might trigger TLR3 on NK 
cells leading to IFN-γ production which in turn, might mediate direct cytotoxic 
effects against the HCC cancer cells, inhibiting cell proliferation and cell cycle arrest.  
Compared with peripheral NK cells, liver NK cells display higher cytotoxicity against 
tumour cells and express more granzyme, perforin and TRAIL [131]. One plausible 
explanation for the difference observed between liver and peripheral NK cells is the 
larger number of Kupffer cells that could play a role in the enrichment and activation 
of liver NK cells. Conditioned medium from Kupffer cells enhances liver NK cells 
viability and, more importantly, tumour cytotoxic activity [132,133]. Therefore it is 
possible that the cytotoxicity towards HCC tumour cells that we observed in our 





4.4 Other indirect effects of TLR3 in controlling tumour progression 
 
Our data suggests that the control of cancer cell proliferation and induction of cell 
death maybe a direct mechanism mediated by TLR3+ cells. However, other less 
direct effects of TLR3 such as the synergistic effect of IFN-γ with other cytokines 
[68], or the recruitment of other immune cells may also contribute to cancer cell death 
or the inhibition of proliferation. 
In our previous study, we have shown that besides CD56 NK cells, CD8+ cells are 
also inversely correlated with proliferating tumours [46]. Stimulation of TLR3 in the 
mouse liver was reported to increase the recruitment and activation of cytopathic CD8 
T cells via the release of TNF-α and IFN-γ [68]. Hence, the release of IFN-γ (from 
NK cells) and TNF-α (which could come from the kupffer cells or 
macrophages)could lead to the recruitment of CD8 T cells. The presence of these 
effector cells (CD8 T cells and NK cells) could lead to the control of tumour 
progression.  
In addition, data from our lab showed that IFN-γ potentiates CXCL10 secretion by 
HCC cells and macrophages. Our data also shows that CXCL10 attracts Th1 and NK 
cells. Therefore our finding suggests that poly I:C-induced expression of IFN-γ by 





4.5 Selective advantage for tumours to loose TLR3 
 
The expression of TLR3 on tumours cells and its association to apoptosis have been 
reported on several cancers including HCC. However the sensitivity of TLR3-positive 
tumour cells to TLR3 triggered apoptosis appears to vary not only between tumours 
but also tumours of the same type (e.g. between different HCC tumours).  The level 
of expression of TLR3 by cancer cells may represent a determinant factor for the 
sensitivity to apoptosis. In our results, we show that as cancer increases in grade or 
when the disease progresses to later stages, tumours generally lose the expression of 
TLR3 (Figure 16). Losing expression of TLR3 may confer a selective advantage for 
the tumours. It is possible that tumours selectively acquire mutations to enhance their 
own survival. Some mutations results in the upregulation of pro-survival molecules 
while other mutations results in the loss of genes that make tumour prone to cell death. 
For example, cancer cells often upregulate pro-survival molecules such as Bcl-2 or 
PI3K, which render them less susceptible to apoptosis. Another example is the 
mutation that leads to the lost of tumour suppressor gene such as p53. As p53 could 
positively regulate TLR3 in human epithelial cell lines [124], the loss of p53 could 
result in a decrease in TLR3 as the tumour progresses. In accordance with this 
observation, Budhu and colleagues have reported that low levels of TLR3 are 




4.6 Clinical significance of TLR3 in HCC 
 
Poly I:C has been shown to be a potent adjuvant in melanoma [69] and human 
cervival cancer xenograph murine tumour models [134]. It was first used clinically 
for its ability to stimulate type I interferons [135] but its toxic side effects such as 
shock, renal failure and hypersensitive reactions led to it being removed from clinical 
use. However with recent data of TLR3 having an anti-tumour effect, Poly I:C has 
been remodified for use in clinical setting in human [136]. Ampligen (a TLR3 
agonist), is now being tested in combination with chemotherapeutic drugs in advance 
ovarian cancer [118] .  
There are a few mechanisms that TLR agonist can result in anti-tumour effect, 
however little focus has been given to the mechanism of TLR3 agonist in HCC. Our 
results show that the induction of TLR3 can result in tumour cell death. The 
immunogenicity of dying cells can represent an important therapeutic advantage. For 
example, HMGB1 released from dying tumour cells act on TLR4 on DC for the 
activation of tumour-specific T cell immunity [137]. Our results also show that 
dsRNA can activate NK cells to kill HCC cells. DsRNA released from dying tumour 
cells could also stimulate NK or specific T cells for efficient anti-tumour response in 
HCC. TLR3 agonist can then be considered as multifunctional adjuvant for cancer 
therapy, combining the induction of immunogenic cell death, the provision of tumour 
antigens and the activation of the immune response.  
81 
 
TLR agonist has been widely explored for the treatment of various cancers, however 
there is no report for the treatment of HCC with TLR3 ligands. Our study supports the 







4.7 Conclusion and perspectives 
 
In summary, our study show that TLR3 on both cancer cell and NK cells are 
associated with prolonged HCC patient survival. The increased expression of TLR3 
might result in control of tumour progression by a few mechanisms. TLR3 can play a 
direct role in controlling tumour progression by causing apoptosis and inhibition of 
proliferation of TLR3 expressing cancer cells. Activation of TLR3-expressing NK 
cells can also result in increased production of IFN-γ and granzyme B thus enhancing 
cytotoxicity towards HCC cells. Other indirect mechanism of activating TLR3, such 
as the synergistic effect of IFN-γ with other cytokines that may recruit other Th1 
effector cells (for e.g. CD8), may also result in the control of tumour progression. 
Although vaccine adjuvants are the most extensively explored application for TLR 
agonist, a growing number of studies have also facilitated the application of TLR 
agonists against cancer. The potential of using TLR agonist in cancer vaccines are 
usually to enhance the CD8 T cell response to protein antigens, which usually 
requires cross presentation of peptides. TLR agonist also provide co-stimulation and 
generate response towards tumour-associated antigens [138]. Although TLR3 
agonists have been in preclinical stage for testing against breast cancer, our findings 
provide the rational for their use in HCC as well. TLR3 agonists can induce apoptosis 
in TLR3-postive HCC tumour and increase anti-tumour innate immunity such as NK 
cells. Other indirect effects such as the synergistic effect of IFN-γ and other 
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